Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals changed its corporate name to Decoy Therapeutics and shifted its public-company identity to preclinical peptide-conjugate therapeutics. Company news centers on Decoy's machine-learning and AI-enabled platform for designing, engineering and manufacturing peptide conjugate drug candidates, with an initial pipeline focused on respiratory viruses and gastrointestinal cancers.
Recurring updates also cover shareholder votes, governance matters, capital-structure actions, Nasdaq listing compliance, and clinical or regulatory disclosures tied to its biotechnology programs.
Salarius Pharmaceuticals (Nasdaq: SLRX) reported significant developments following a $6.2 million public offering closed on August 3, 2020. The company recorded a net loss of $1.8 million for Q2 2020, down from $0.9 million in the previous year, with increased R&D and administrative costs contributing to losses. Salarius is expanding its clinical trial for seclidemstat to include Ewing-related sarcomas, supported by promising preliminary data. Current cash reserves stand at $7.2 million, with additional funding opportunities available through the CPRIT contract.
Salarius Pharmaceuticals (SLRX) announced a conference call on August 12, 2020, at 4:30 p.m. ET, to present its Q2 2020 corporate and financial results. The company is focused on treating cancers linked to dysregulated gene expression, with its lead candidate, seclidemstat, in Phase 1/2 trials, specifically for Ewing sarcoma.
Salarius has received several designations from the FDA, including Fast Track and Orphan Drug Designations. The company also secured financial support for its clinical programs, including an $18.7 million award from CPRIT.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced the issuance of a European patent for its lead compound, seclidemstat, which targets cancers caused by dysregulated gene expression. The European Patent EP2744330 was issued on July 15, 2020, and covers both composition and methods of use for seclidemstat, currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. Salarius aims to validate this patent across major EU countries, ensuring protection until at least August 2032. The company holds 24 issued patents globally and has additional applications pending.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announced a public offering of 4,461,209 shares of its common stock priced at $1.20 per share, aiming to raise approximately $5.3 million before expenses. The offering is expected to close on August 3, 2020, pending customary conditions. Ladenburg Thalmann & Co. Inc. is the sole book-running manager. Salarius focuses on treating cancers linked to dysregulated gene expression, with their lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma and other cancers.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced the launch of an underwritten public offering of its common stock. The offering, managed by Ladenburg Thalmann & Co. Inc., is subject to market conditions and may not be completed as planned. The company has a shelf registration statement effective as of May 17, 2019. Salarius focuses on developing treatments for cancers linked to dysregulated gene expression, with its lead candidate, seclidemstat, under clinical evaluation for Ewing sarcoma and other tumors. Risks related to the offering and market conditions are highlighted in the release.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced the expansion of its ongoing clinical trial for seclidemstat, aimed at treating relapsed Ewing sarcoma, to include Ewing-related sarcomas sharing similar biology. Pre-clinical and early clinical data show promise, with one refractory patient showing an 80% reduction in target lesions. The trial will also enroll up to 30 patients with related sarcomas. This move indicates Salarius' belief in seclidemstat's potential efficacy and aims to broaden its application in treating sarcomas, addressing a significant medical need.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that an abstract on its Phase 1/2 clinical trial of seclidemstat for Ewing sarcoma has been accepted for presentation at the ASCO Virtual Scientific Program from May 29-31, 2020. The trial aims to assess seclidemstat's safety and tolerability in relapsed/refractory Ewing sarcoma patients. David Arthur, CEO, noted significant advances in dose escalation and enrollment over the past year. Seclidemstat addresses a critical unmet need in treating this rare cancer, with various designations from the FDA supporting its development.
Summary not available.